Related Experiment Video
Updated: Jul 8, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease
1Cattedra di Medicina Interna (Ospedale S. Gerardo, Monza), Milan, Italy.
Insights
Angiotensin converting enzyme (ACE) inhibition reduces sympathetic coronary vasoconstriction in patients with coronary artery disease. This effect is likely due to blocking angiotensin II's influence on coronary blood flow regulation.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Background:
- Sympathetic stimulation typically causes vasoconstriction in peripheral arteries.
- The effect of angiotensin converting enzyme (ACE) inhibition on sympathetic coronary vasoconstriction is not well understood.
Purpose of the Study:
- To investigate whether ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease.
Main Methods:
- Nine patients with coronary atherosclerosis underwent cold pressor tests and diving stimuli.
- Measurements included arterial pressure, heart rate, coronary sinus blood flow (CBF), and coronary vascular resistance (CVR).
- Measurements were taken before and after oral administration of captopril (an ACE inhibitor).
Main Results:
- Without captopril, sympathetic stimuli increased coronary vascular resistance (CVR) and reduced coronary blood flow (CBF).
- Captopril did not significantly alter blood pressure or heart rate responses to stimuli.
- Captopril markedly attenuated the increase in CVR during sympathetic stimulation.
Conclusions:
- ACE inhibition effectively reduces sympathetic coronary vasoconstriction in patients with coronary artery disease.
- This attenuation is likely mediated by the removal of angiotensin II's facilitating effect on sympathetic coronary vasomotor tone.
Background:
In humans, angiotensin converting enzyme (ACE) inhibition attenuates the vasoconstriction induced by sympathetic stimulation in a number of peripheral districts. Whether this is also the case in the coronary circulation is unknown, however.
Methods And Results:
In nine normotensive patients with angiographically assessed coronary atherosclerosis, we measured the changes in mean arterial pressure (intra-arterial catheter), heart rate, rate-pressure product (RPP), coronary sinus blood flow (CBF, thermodilution method), and coronary vascular resistance (CVR, ratio between mean arterial pressure and CBF) induced by the cold pressor test (CPT, 2 minutes) and diving (30 seconds), i.e., two stimuli eliciting a sympathetic coronary vasoconstriction. The measurements were performed in the control condition and 30 minutes after captopril 25 mg p.o. In the control condition, CPT caused an increase in mean arterial pressure and heart rate. Despite the increase in RPP (+20.7 +/- 3.2%, p less than 0.01), CBF did not change and CVR increased (+12.2 +/- 4.0%, p less than 0.05). diving caused an increase in mean arterial pressure and a reduction in heart rate. RPP increased (+14.3 +/- 3.5%, p less than 0.01), but despite this increase, there was a reduction in CBF and a marked increase in CVR (+37.3 +/- 7.4%, p less than 0.01). Captopril did not modify the blood pressure and heart rate responses to both stimuli except for a slight accentuation of the bradycardia to diving. Despite the unchanged or only slightly reduced RPP response, the increase in CVR was markedly and significantly attenuated (p less than 0.01).
Conclusions:
ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. This is probably due to removal of the facilitating influence of angiotensin II on sympathetic modulation of coronary vasomotor tone.
Related Concept Videos
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers
Coronary Artery Disease V: Interprofessional Care
Heart Failure V: Medical Management

